(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.90%154.120.0%$3252.67m
BIIBBiogen, Inc. 0.70%241.851.7%$680.44m
NVAXNovavax, Inc. -8.16%128.1292.9%$616.11m
AMGNAmgen, Inc. 0.90%224.051.3%$578.92m
BNTXBioNTech SE -4.77%118.320.0%$578.83m
GILDGilead Sciences, Inc. 1.86%61.801.0%$530.62m
VRTXVertex Pharmaceuticals, Inc. 0.64%229.201.9%$503.04m
REGNRegeneron Pharmaceuticals, Inc. 1.55%524.012.7%$497.50m
ILMNIllumina, Inc. 3.35%332.893.5%$389.77m
APVOAptevo Therapeutics, Inc. 0.62%44.0018.3%$243.82m
SGENSeagen Inc. 4.50%177.985.8%$183.88m
EXASEXACT Sciences Corp. 3.54%125.3419.6%$179.25m
ALXNAlexion Pharmaceuticals, Inc. -0.50%121.502.0%$148.68m
HALOHalozyme Therapeutics, Inc. 2.69%40.1518.4%$137.65m
SRNESorrento Therapeutics, Inc. -1.96%8.041.4%$137.06m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.